|
Real-world racial disparities in EGFR testing and third-generation EGFR TKI use among U.S. patients with stage IV NSCLC. |
| |
|
Employment - Alnylam (I); EQRx |
Stock and Other Ownership Interests - Alnylam (I); EQRx |
| |
|
|
Stock and Other Ownership Interests - EQRx |
| |
|
Employment - EQRX; Foundation Medicine |
Leadership - Revolution Medicines |
Stock and Other Ownership Interests - EQRX; Foundation Medicine; Mirati Therapeutics; Revolution Medicines |
Patents, Royalties, Other Intellectual Property - Receive periodic royalties related to T790M patent awarded to Memorial Sloan Kettering Cancer Center |
| |
|
No Relationships to Disclose |
| |
|
Employment - EQRX; EQRX (I) |
Leadership - Droplet Biosciences; Elevation Oncology; Incysus; Pillar Biosciences |
Stock and Other Ownership Interests - Exelixis; Merus NV; Pfizer; Pfizer |
Consulting or Advisory Role - Archer; Azitra (I); Princeptx (I) |
Patents, Royalties, Other Intellectual Property - patents via FOundation Medicine; Patents via Seres Health on microbiome stuff in non neoplastic disease (I) |